* | Page 1 | Search Results | Emerging Technologies and Data Science

1-20 of 25 Search Results for

*

Sort by

Sort Order Select

Journal Articles

Targeting pancreatic cancer cell stemness by blocking fibronectin-binding integrins on cancer-associated fibroblasts

Chengsheng Wu, Tami von Schalscha, Diva Sansanwal, Chen Qian, Qinlin Jiang, Ryan M. Shepard, Hiromi I. Wettersten, Stephen J. McCormack, Sara M. Weis, David A. Cheresh

Cancer Research Communications (2025)

https://doi.org/10.1158/2767-9764.CRC-24-0491

Published: 09 January 2025

View article titled, Targeting pancreatic cancer cell stemness by blocking fibronectin-binding integrins on cancer-associated fibroblasts

Includes: Supplementary data

Journal Articles

ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors

Cancer Research Communications (2024) 4 (11): 2998–3012.

https://doi.org/10.1158/2767-9764.CRC-24-0176

Published: 22 November 2024

View article titled, ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors

Includes: Supplementary data

Journal Articles

Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers

Maxim Kuznetsov, Vikram Adhikarla, Enrico Caserta, Xiuli Wang, John E. Shively, Flavia Pichiorri, Russell C. Rockne

Cancer Research Communications (2024) 4 (11): 2955–2967.

https://doi.org/10.1158/2767-9764.CRC-24-0306

Published: 14 November 2024

View article titled, Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers

Includes: Supplementary data

Journal Articles

Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models

Zhanfang Guo, Jingqin Luo, R. Jay Mashl, Jeremy Hoog, Piyush Maiti, Nikki Fettig, Sherri R. Davies, Rebecca Aft, Jason M. Held, Ramaswamy Govindan, Li Ding, Shunqiang Li, Cornelius von Morze, Gerburg M. Wulf, Kooresh I. Shoghi, Cynthia X. Ma

Cancer Research Communications (2024) 4 (6): 1430–1440.

https://doi.org/10.1158/2767-9764.CRC-24-0047

Published: 05 June 2024

View article titled, Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models

Includes: Supplementary data

Journal Articles

Exercise-induced β2-adrenergic Receptor Activation Enhances the Antileukemic Activity of Expanded γδ T-Cells via DNAM-1 Upregulation and PVR/Nectin-2 Recognition

Forrest L. Baker, Kyle A. Smith, Preetesh L. Mylabathula, Tiffany M. Zúñiga, Douglass M. Diak, Helena Batatinha, Grace M. Niemiro, Michael D. Seckeler, Charles R. Pedlar, Daniel P. O'Connor, Jamie Colombo, Emmanuel Katsanis, Richard J. Simpson

Cancer Research Communications (2024) 4 (5): 1253–1267.

https://doi.org/10.1158/2767-9764.CRC-23-0570

Published: 13 May 2024

View article titled, Exercise-induced β2-adrenergic Receptor Activation Enhances the Antileukemic Activity of Expanded γδ T-Cells via DNAM-1 Upregulation and PVR/Nectin-2 Recognition

Includes: Supplementary data

Journal Articles

Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts

Cancer Research Communications (2024) 4 (3): 834–848.

https://doi.org/10.1158/2767-9764.CRC-24-0085

Published: 19 March 2024

View article titled, Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts

Includes: Supplementary data

Journal Articles

Establishment and Characterization of an Epstein-Barr Virus–positive Cell Line from a Non-keratinizing Differentiated Primary Nasopharyngeal Carcinoma

Cancer Research Communications (2024) 4 (3): 645–659.

https://doi.org/10.1158/2767-9764.CRC-23-0341

Published: 04 March 2024

View article titled, Establishment and Characterization of an Epstein-Barr Virus–positive Cell Line from a Non-keratinizing Differentiated Primary Nasopharyngeal Carcinoma

Includes: Supplementary data

Journal Articles

Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer

Nitin Roper, Rajaa El Meskini, Tapan Maity, Devon Atkinson, Amanda Day, Nathan Pate, Constance M. Cultraro, Svetlana Pack, Valerie Zgonc, Zoe Weaver Ohler, Udayan Guha

Cancer Research Communications (2024) 4 (2): 337–348.

https://doi.org/10.1158/2767-9764.CRC-23-0321

Published: 08 February 2024

View article titled, Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer

Includes: Supplementary data

Journal Articles

Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Emanuela Gentile, Andrew W. Hahn, Jian H. Song, Anh Hoang, Peter D. A. Shepherd, Sumankalai Ramachandran, Nora M. Navone, Eleni Efstathiou, Mark Titus, Paul G. Corn, Sue-Hwa Lin, Christopher J. Logothetis, Theocharis Panaretakis

Cancer Research Communications (2023) 3 (12): 2531–2543.

https://doi.org/10.1158/2767-9764.CRC-23-0362

Published: 13 December 2023

View article titled, Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Includes: Supplementary data

Journal Articles

Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance

William Echavidre, Jérôme Durivault, Célia Gotorbe, Thays Blanchard, Marina Pagnuzzi, Valérie Vial, Florian Raes, Alexis Broisat, Rémy Villeneuve, Régis Amblard, Nicolas Garnier, Cécile Ortholan, Marc Faraggi, Benjamin Serrano, Vincent Picco, Christopher Montemagno

Cancer Research Communications (2023) 3 (12): 2483–2496.

https://doi.org/10.1158/2767-9764.CRC-23-0298

Published: 07 December 2023

View article titled, Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance

Includes: Supplementary data

Journal Articles

Statistical Assessment of Drug Synergy from In Vivo Combination Studies Using Mouse Tumor Models

Binchen Mao, Sheng Guo

Cancer Research Communications (2023) 3 (10): 2146–2157.

https://doi.org/10.1158/2767-9764.CRC-23-0243

Published: 23 October 2023

View article titled, Statistical Assessment of Drug Synergy from <em>In Vivo</em> Combination Studies Using Mouse Tumor Models

Journal Articles

HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer

Devra Olson, Janelle Taylor, Kelsi Willis, Kelly Hensley, Sean Allred, Margo Zaval, Lauren Farr, Robert Thurman, Nishi Jain, Renee Hein, Michelle Ulrich, Scott Peterson, Anita Kulukian

Cancer Research Communications (2023) 3 (9): 1927–1939.

https://doi.org/10.1158/2767-9764.CRC-23-0302

Published: 25 September 2023

View article titled, HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer

Includes: Supplementary data

Journal Articles

Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade

Cancer Research Communications (2023) 3 (8): 1564–1579.

https://doi.org/10.1158/2767-9764.CRC-22-0293

Published: 16 August 2023

View article titled, Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade

Includes: Multimedia, Supplementary data

Journal Articles

Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment

Aki Morikawa, Jinju Li, Peter Ulintz, Xu Cheng, Athena Apfel, Dan Robinson, Alex Hopkins, Chandan Kumar-Sinha, Yi-Mi Wu, Habib Serhan, Kait Verbal, Dafydd Thomas, Daniel F. Hayes, Arul M. Chinnaiyan, Veerabhadran Baladandayuthapani, Jason Heth, Matthew B. Soellner, Sofia D. Merajver, Nathan Merrill

Cancer Research Communications (2023) 3 (6): 1093–1103.

https://doi.org/10.1158/2767-9764.CRC-22-0492

Published: 21 June 2023

View article titled, Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment

Includes: Supplementary data

Journal Articles

The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin

Giulia Dellavedova, Alessandra Decio, Laura Formenti, Mark R. Albertella, Joanne Wilson, Anna D. Staniszewska, Elisabetta Leo, Raffaella Giavazzi, Carmen Ghilardi, Maria Rosa Bani

Cancer Research Communications (2023) 3 (3): 489–500.

https://doi.org/10.1158/2767-9764.CRC-22-0423

Published: 27 March 2023

View article titled, The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin

Includes: Supplementary data

Journal Articles

Humanized Patient-derived Xenograft Models of Disseminated Ovarian Cancer Recapitulate Key Aspects of the Tumor Immune Environment within the Peritoneal Cavity

Mara P. Steinkamp, Irina Lagutina, Kathryn J. Brayer, Fred Schultz, Danielle Burke, Vernon S. Pankratz, Sarah F. Adams, Laurie G. Hudson, Scott A. Ness, Angela Wandinger-Ness

Cancer Research Communications (2023) 3 (2): 309–324.

https://doi.org/10.1158/2767-9764.CRC-22-0300

Published: 22 February 2023

View article titled, Humanized Patient-derived Xenograft Models of Disseminated Ovarian Cancer Recapitulate Key Aspects of the Tumor Immune Environment within the Peritoneal Cavity

Includes: Supplementary data

Journal Articles

Mouse Stromal Cells Confound Proteomic Characterization and Quantification of Xenograft Models

Zhaomei Shi, Binchen Mao, Xiaobo Chen, Piliang Hao, Sheng Guo

Cancer Research Communications (2023) 3 (2): 202–214.

https://doi.org/10.1158/2767-9764.CRC-22-0431

Published: 06 February 2023

View article titled, Mouse Stromal Cells Confound Proteomic Characterization and Quantification of Xenograft Models

Includes: Supplementary data

Journal Articles

On the Choice of Longitudinal Models for the Analysis of Antitumor Efficacy in Mouse Clinical Trials of Patient-derived Xenograft Models

Hélène Savel, Sandrine Barbier, Cécile Proust-Lima, Virginie Rondeau, Rodolphe Thiébaut, Florence Meyer-Losic, Laura Richert

Cancer Research Communications (2023) 3 (1): 140–147.

https://doi.org/10.1158/2767-9764.CRC-22-0238

Published: 26 January 2023

View article titled, On the Choice of Longitudinal Models for the Analysis of Antitumor Efficacy in Mouse Clinical Trials of Patient-derived Xenograft Models

Includes: Supplementary data

Journal Articles

Characterization of Novel Derivatives of MBQ-167, an Inhibitor of the GTP-binding Proteins Rac/Cdc42

Julia I. Medina, Ailed Cruz-Collazo, Maria del Mar Maldonado, Tatiana Matos Gascot, Luis D. Borrero-Garcia, Mariana Cooke, Marcelo G. Kazanietz, Eliud Hernandez O'Farril, Cornelis P. Vlaar, Suranganie Dharmawardhane

Cancer Research Communications (2022) 2 (12): 1711–1726.

https://doi.org/10.1158/2767-9764.CRC-22-0303

Published: 29 December 2022

View article titled, Characterization of Novel Derivatives of MBQ-167, an Inhibitor of the GTP-binding Proteins Rac/Cdc42

Includes: Supplementary data

Journal Articles

Targeting MLL Methyltransferases Enhances the Antitumor Effects of PI3K Inhibition in Hormone Receptor–positive Breast Cancer

Robert B. Jones, Jonathan Farhi, Miranda Adams, Kiran K. Parwani, Garrett W. Cooper, Milica Zecevic, Richard S. Lee, Andrew L. Hong, Jennifer M. Spangle

Cancer Research Communications (2022) 2 (12): 1569–1578.

https://doi.org/10.1158/2767-9764.CRC-22-0158

Published: 06 December 2022

View article titled, Targeting MLL Methyltransferases Enhances the Antitumor Effects of PI3K Inhibition in Hormone Receptor–positive Breast Cancer

Includes: Supplementary data

NARROW

*

Targeting pancreatic cancer cell stemness by blocking fibronectin-binding integrins on cancer-associated fibroblasts

ETx-22, a Novel Nectin-4–Directed Antibody–Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4–Expressing Tumors

Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers

Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models

Exercise-induced β2-adrenergic Receptor Activation Enhances the Antileukemic Activity of Expanded γδ T-Cells via DNAM-1 Upregulation and PVR/Nectin-2 Recognition

Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts

Establishment and Characterization of an Epstein-Barr Virus–positive Cell Line from a Non-keratinizing Differentiated Primary Nasopharyngeal Carcinoma

Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer

Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer

Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance

Statistical Assessment of Drug Synergy from In Vivo Combination Studies Using Mouse Tumor Models

HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer

Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade

Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment

The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin

Humanized Patient-derived Xenograft Models of Disseminated Ovarian Cancer Recapitulate Key Aspects of the Tumor Immune Environment within the Peritoneal Cavity

Mouse Stromal Cells Confound Proteomic Characterization and Quantification of Xenograft Models

On the Choice of Longitudinal Models for the Analysis of Antitumor Efficacy in Mouse Clinical Trials of Patient-derived Xenograft Models

Characterization of Novel Derivatives of MBQ-167, an Inhibitor of the GTP-binding Proteins Rac/Cdc42

Targeting MLL Methyltransferases Enhances the Antitumor Effects of PI3K Inhibition in Hormone Receptor–positive Breast Cancer

AACR Journals

*

AACR Journals

This Feature Is Available To Subscribers Only